Meta-analysis of vascular and neoplastic events associated with tamoxifen
Open Access
- 1 November 2003
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of General Internal Medicine
- Vol. 18 (11), 937-947
- https://doi.org/10.1046/j.1525-1497.2003.20724.x
Abstract
No abstract availableKeywords
This publication has 66 references indexed in Scilit:
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJama-Journal Of The American Medical Association, 2002
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 2002
- Reducing the Risk of Breast CancerThe New England Journal of Medicine, 2000
- Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy. Report from the Danish Breast Cancer Co-operative Group DBCG 82B trialEuropean Journal of Cancer, 1999
- Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trialThe Lancet, 1998
- Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised womenThe Lancet, 1998
- Tamoxifen Inhibits Arterial Accumulation of LDL Degradation Products and Progression of Coronary Artery Atherosclerosis in MonkeysArteriosclerosis, Thrombosis, and Vascular Biology, 1997
- Cardiac and Thromboembolic Morbidity Among Postmenopausal Women With Early Stage Breast Cancer in a Randomized Trial of Adjuvant TamoxifenJNCI Journal of the National Cancer Institute, 1993
- Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly patients: 5-year follow-upEuropean Journal of Cancer, 1992
- Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (breast cancer adjuvant chemo-hormone therapy cooperative group) trialEuropean Journal of Cancer, 1992